GlobeNewsWire
24 Jul 2026, 01:08 UTC · 3h ago
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
24 Jul 2026, 01:08 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Scribe Therapeutics is pricing its upsized IPO at the high end of its range at $15.00 per share. — Pricing at the top of the range and upsizing the offering indicates strong institutional demand for the company's CRISPR technology.
+0.60Sanofi is participating in a concurrent private placement to purchase 500,000 shares of Scribe Therapeutics at $15.00 per share. — Direct investment from a major pharmaceutical player like Sanofi serves as a strong validation of the company's underlying science and platform.
+0.50The IPO is expected to generate gross proceeds of $128.7 million. — Provides the clinical-stage company with significant non-dilutive capital to fund its lead candidate and pipeline development.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is successfully launching an upsized IPO priced at the high end of the range.
Mentioned only as a joint book-running manager for the IPO.
Mentioned as a strategic collaborator.
Mentioned as a strategic collaborator and participant in a private placement.
Mentioned only as a joint book-running manager for the IPO.
[mutual] Scribe Therapeutics has a strategic collaboration with Sanofi and sold shares to them in a private placement.
[mutual] Scribe Therapeutics has formed a strategic collaboration with Eli Lilly.
[a_to_b] Goldman Sachs is acting as a joint book-running manager for Scribe Therapeutics' IPO.
[a_to_b] Wells Fargo Securities is acting as a joint book-running manager for Scribe Therapeutics' IPO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
47m ago
